15 Aug What are the effects of CPAP therapy termination in the first year on all-cause mortality in patients with OSA.
Data were analysed from the Système National des Données de Santé (SNDS) database, the French national health insurance reimbursement system, for all new CPAP users ≥ 18 years of age. The French SNDS is currently one of the best anonymized claims databases in the world because of its size (600 terabytes) and its unbiased recruitment (including > 99% of the total French population).
Over a 3-year observation period, death occurred in 3,204 of 88,007 patients (3.6%) in the CPAP therapy termination group compared with 2,053 of 88,007 patients (2.3%) in the therapy continuation group
The cumulative incidence of heart failure was significantly lower in patients who continued vs terminated CPAP therapy (HR, 0.77; 95% CI, 0.71-0.82; P < .01). During follow-up, incident hypertension and heart failure occurred significantly less frequently in patients with OSA who continued vs terminated CPAP therapy. In addition, a trend toward a lower risk of new hospitalizations for diabetes in the therapy continuation vs therapy termination group was found (P = .06)
This study showed that continued use of CPAP during the first year after therapy initiation is associated with a significant reduction in mortality in a large national cohort of patients with OSA compared with CPAP therapy termination. This finding adds to a growing body of evidence for the beneficial effects of CPAP use on survival.
